Alessandra Cipriano

Alessandra Cipriano

Auto-generated profile, based on publicly available information

Alessandra Cipriano

Department of Pharmacy University of Salerno Via Giovanni Paolo II 132 84084 Fisciano SA Italy

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Journal of Enzyme Inhibition and Medicinal Chemistry
Verified
Journal Article
Open access
CMCiro Milite
Ciro Milite
GAGiorgio Amendola
Giorgio Amendola
Alessio NocentiniAlessio Nocentini
Alessio Nocentini
SBSilvia Bua
Silvia Bua
ACAlessandra Cipriano
Alessandra Cipriano
STSabrina Taliani
Sabrina Taliani
Inhibition of Carbonic Anhydrases (CAs) has been clinically exploited for many decades for a variety of therapeutic applications. Within a research project aimed at developing novel classes of CA inhibitors (CAIs) with a proper selectivity for certain isoforms, a series of derivatives featuring the 2-substituted-benzimidazole-6-sulfonamide scaffold, conceived as frozen analogs of Schiff bases and secondary amines previously reported in the literature as CAIs, were investigated. Enzyme inhibition assays on physiologically relevant human CA I, II, IX and XII isoforms revealed a number of potent CAIs, showing promising selectivity profiles towards the transmembrane tumor-associated CA IX and XII enzymes. Computational studies were attained to clarify the structural determinants behind the activities and selectivity profiles of the novel inhibitors. Graphical Abstract

1 August 2020 in Current Opinion in Chemical Biology
Verified
Journal Article
Closed access
ACAlessandra Cipriano
Alessandra Cipriano
GGianluca Sbardella
Gianluca Sbardella
ACAlessio Ciulli
Alessio Ciulli

15 September 2022 in ChemMedChem
Verified
Journal Article
Open access
ACAlessandra Cipriano
Alessandra Cipriano
CMCiro Milite
Ciro Milite
AFAlessandra Feoli
Alessandra Feoli
MVMonica Viviano
Monica Viviano
Giacomo PepeGiacomo Pepe
Giacomo Pepe
GGianluca Sbardella
Gianluca Sbardella
The bromodomain and extra‐terminal (BET) family of proteins includes BRD2, BRD3, BRD4, and the testis‐specific protein, BRDT, each containing two N‐terminal tandem bromodomain (BRD) modules. Potent and selective inhibitors targeting the two bromodomains are required to elucidate their biological role(s), with potential clinical applications. In this study, we designed and synthesized a series of benzimidazole‐6‐sulfonamides starting from the azobenzene compounds MS436 (7 a) and MS611 (7 b) that exhibited preference for the first (BD1) over the second (BD2) BRD of BET family members. The most‐promising compound (9 a) showed good binding potency and improved metabolic stability and selectivity towards BD1 with respect to the parent compounds.

25 June 2024 in ChemMedChem
Verified
Journal Article
Open access
CMCiro Milite
Ciro Milite
GSGiuliana Sarno
Giuliana Sarno
IPIda Pacilio
Ida Pacilio
ACAgostino Cianciulli
Agostino Cianciulli
MVMonica Viviano
Monica Viviano
GGianluca Sbardella
Gianluca Sbardella
Protein arginine methyltransferase (PRMT) 4 (also known as coactivator‐associated arginine methyltransferase 1; CARM1) is involved in a variety of biological processes and is considered as an emerging target class in oncology and other diseases. A successful strategy to identify PRMT substrate‐competitive inhibitors has been to exploit chemical scaffolds able to mimic the arginine substrate. (S)‐Alanine amide moiety is a valuable arginine mimic for the development of potent and selective PRMT4 inhibitors; however, its high hydrophilicity led to derivatives with poor cellular outcomes. Here, we describe the development of PRMT4 inhibitors featuring a central pyrrole core and an alanine amide moiety. Rounds of optimization, aimed to increase lipophilicity and simultaneously preserve the inhibitory activity, produced derivatives that, despite good potency and physicochemical properties, did not achieve on‐target effects in cells. On the other hand, masking the amino group with a NAD(P)H:quinone oxidoreductase 1 (NQO1)‐responsive trigger group, led to prodrugs able to reduce arginine dimethylation of the PRMT4 substrates BRG1‐associated factor 155 (BAF155). These results indicate that prodrug strategies can be successfully applied to alanine‐amide containing PRMT4 inhibitors and provide an option to enable such compounds to achieve sufficiently high exposures in vivo.

1 April 2020 in SLEEP
Verified
Journal Article
Open access
PDF file
MZM Zhou
M Zhou
SHS Harris
S Harris
RKR Kapil
R Kapil
ACA Cipriano
A Cipriano
EHE He
E He
GZG Zammit
G Zammit
V117957 is a recently described investigational oral, potent, and selective nociceptin/orphanin-FQ peptide (NOP) receptor partial agonist which was previously evaluated in ~200 healthy subjects. Its satisfactory safety/tolerability profile has been established with the top doses at 30mg following a single oral administration and 10mg once daily for 2 weeks. V117957 demonstrated favorable drug-like properties for insomnia treatment, including oral bioavailability, fast absorption, and rapid elimination. A total of 52 patients with insomnia disorder have been evaluated in two separate randomized, double-blind, crossover, placebo-controlled sleep studies. Insomnia disorder was confirmed by screening polysomnography (PSG). All subjects received orally, for two consecutive nights, either V117957 10mg or placebo in Study #1 or 0.5, 1, 3, 6mg or placebo in Study #2. Efficacy was measured via PSG for the primary endpoint of sleep efficiency (SE) and secondary endpoints of sleep onset (latency to persistent sleep [LPS]) and maintenance (wakefulness after sleep onset [WASO]). Efficacy also was measured by patient diary (subjective sleep latency [sSL], subjective total sleep time [sTST], sWASO). Pharmacodynamics (PD) on next-day residual effects were also measured, including cognitive, psychomotor and mood effects. V117957 showed statistically significant greater sleep efficiency and less WASO in a dose-dependent manner (0.5-10 mg) and a statistically significant reduction in LPS at 10mg, as compared to placebo. V117957 at 0.5mg and 1mg exhibited next-day residual effects similar to placebo. At doses of 3mg or higher, V117957 showed dose-dependent next-day residual effects. V117957 was safe and well-tolerated across all doses tested with no serious adverse events, with somnolence being the most frequent treatment-emergent adverse event. No concerning laboratory findings and no clinically significant findings on vital signs and electrocardiograms have been attributed to V117957 in these subjects. V117957 was safe and well-tolerated in patients with insomnia disorder. These results demonstrated that NOP receptors represent a novel mechanistic treatment for insomnia disorder and support continued evaluation of V117957. Funded by Shionogi and Imbrium Therapeutics, a subsidiary of Purdue Pharma L.P.

1 September 2026 in RSC Medicinal Chemistry
Verified
Journal Article
Open access
MVMonica Viviano
Monica Viviano
ACAlessandra Cipriano
Alessandra Cipriano
BDBenito D'AScoli
Benito D'AScoli
CMCiro Milite
Ciro Milite
SCSabrina Castellano
Sabrina Castellano
GGianluca Sbardella
Gianluca Sbardella
A comprehensive overview of PRMT small-molecule inhibitors and degraders, covering structural classification, allosteric and MTA-cooperative strategies, and novel targeted degradation modalities.